Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies

The Chimeric antigen receptor (CAR)-T cell therapy has made inroads in treating hematological malignancies. Nonetheless, there are still multiple hurdles in CAR-T cell therapy for solid tumors. Primary CAR-expressing macrophage cells (CAR-Ms) and induced pluripotent stem cells (iPSCs)-derived CAR-expressing macrophage cells (CAR-iMacs) have emerged as attractive alternatives in our quest for an efficient and inexpensive approach for tumor immune cell therapy. In this review, we list the current state of development of human CAR-macrophages and provide an overview of the crucial functions of human CAR-macrophages in the field of tumor immune cell therapy.

Automated summary

CAR-T cell therapy has achieved progress in treating hematological malignancies, but faces multiple challenges in treating solid tumors. CAR-Ms and CAR-iMacs are considered as efficient and inexpensive alternatives for tumor immune cell therapy. This review outlines the current development of human CAR-macrophages and highlights their crucial functions in the field of tumor immune cell therapy.